Table 1.
Study | Platform | Num. samples typed | Max. multiplex | Phasing | Chimera removal | Fusion calling | Copy num. | End-to-end pipeline available |
---|---|---|---|---|---|---|---|---|
Ammar et al.27 | ONT MinION | 1 | 1 | Yes | No | No | qPCR | No |
Qiao et al.24 | PacBio RS II | 39 | NP | Noa | No | No | qPCR | No |
Buermans et al.25 | PacBio RS II | 25 | 24 | Yes | Yes | PCR | PCRb | No |
Liau et al.26 | ONT GridION | 32 | 24 | Yes | No | No | PCRb | No |
This study | PacBio Sequel I/II | 365 | 95 | Yes | Yes | PCR + Seq | qPCR | Yes |
NP not provided.
aPhasing performed for a subset of samples using additional allele-specific PCR, not long-read sequencing.
bPresence of duplication and deletion PCR products checked, however precise copy numbers of duplications were not attained.